Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Liabilities and Shareholders Equity (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $51.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity changed N/A to $51.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $239.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $51.8 million for FY2025, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $51.8 million at Actinium Pharmaceuticals, down from $56.2 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $121.8 million in Q2 2022, with the low at $51.8 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $85.4 million, with a median of $84.5 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 44.22% in 2022, then tumbled 31.62% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $80.4 million in 2021, then skyrocketed by 42.05% to $114.2 million in 2022, then decreased by 28.68% to $81.4 million in 2023, then increased by 0.82% to $82.1 million in 2024, then tumbled by 36.95% to $51.8 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $51.8 million, $56.2 million, and $63.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.